How do I buy Abivax SA American Depositary Shares (ABVX) stock?

Buying Abivax SA American Depositary Shares (ABVX) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "ABVX", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ABVX by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for ABVX on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Abivax SA American Depositary Shares from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Abivax SA American Depositary Shares (ABVX) pay dividends?

At the moment, Abivax SA American Depositary Shares (ABVX) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ABVX's performance via the price chart in the Gotrade app.

Is buying ABVX on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy ABVX?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if ABVX is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Abivax SA American Depositary Shares (ABVX) Stock Price: Nov 11 Close $91.44

Latest news

Stocktwits

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

ABVXOctober 12, 2026

Stocktwits

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

ABVX

Zacks Investment Research

Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

ABVXJuly 10, 2026

CNBC

Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

ABVX

MarketBeat

Abivax: Wall Street Catches Up to the Data

ABVXJuly 7, 2026

MarketBeat

Abivax: Wall Street Catches Up to the Data

ABVX

Stocktwits

ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds

ABVXJuly 2, 2026

Stocktwits

ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds

ABVX

Reuters

Abivax nears $11 billion valuation after fundraising eases M&A pressure

ABVXJuly 1, 2026

Reuters

Abivax nears $11 billion valuation after fundraising eases M&A pressure

ABVX

Stocktwits

ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns

ABVXJuly 1, 2026

Stocktwits

ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns

ABVX

Proactive Investors

Abivax shares jump as updated trial data eases safety concerns

ABVXJune 30, 2026

Proactive Investors

Abivax shares jump as updated trial data eases safety concerns

ABVX

News tone: automated (AI) classification of the article's content, not a price prediction.

About Abivax SA American Depositary Shares

No description available.

SectorHealthcare

IndustryBiotechnology

Employees98

CEOMr. Marc M. P. de Garidel M.B.A.

IPO DateOct 20, 2023

HeadquartersParis, France

Key Executives

Name	Title	Year Born
Mr. Marc M. P. de Garidel M.B.A.	CEO & Director	1958
Mr. Didier Blondel	EVP, CFO & Board Secretary	1964
Dr. David Zhang Ph.D.	Chief Strategy Officer	1968
Dr. Keith M. Fournier Ph.D.	Senior Vice President of Global Regulatory Affairs	—
Mr. Michael Nesrallah M.B.A.	Chief Commercial Officer	—
Dr. Maurus de la Rosa Ph.D.	Senior Vice President of Research	—
Mr. Ivan Nunez-Pacheco	Global Head of Patient Services	—
Ms. Heather Dean	Global Head of Sales, Accounts & Commercial Operations	—
Mr. Jeffrey N. Haas	Global Head of Market Access & Pricing	—

Fundamentals

Valuation

Price-to-sales ratio1,335.25

Price-to-book value17.14

Profitability

Return on Equity-91.00%

Return on Assets-72.00%

Return on Sales-4972.00%

Gross margin (latest quarter)87.62%

EBITDA$-283.92M

Trading

Average volume906,014

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 51.71
MACD 12/26/9: -1.81
EMA 9 of MACD: -2.72
MACD histogram: 0.91
SMA 50: $95.79; Price below SMA 50
EMA 50: $95.55; Price below EMA 50
SMA 200: $112.82; Price below SMA 200
EMA 200: $109.53; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

6 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

83% Buy

17% Hold

0% Sell

Analyst price target

Low: $96.00
Average: $150.00
High: $175.00

Goldman Sachs

Rajan Sharma

Buy

Target price

$155.00

Barclays

Etzer Darout

Buy

Target price

$148.00

Guggenheim

Yatin Suneja

Buy

Target price

$175.00

Wedbush

David Nierengarten

Hold

Target price

$96.00

Truist Securities

Gregory Renza

Buy

Target price

$151.00

BTIG

Julian Harrison

Buy

Target price

$175.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2023										+10.8	+4.0	+6.3
2024	+22.0	+3.3	+2.6	+7.4	-6.9	-1.9	-12.9	+8.1	-7.2	-5.9	-16.9	-13.7
2025	-18.1	+29.3	-14.7	+20.9	-12.9	+20.5	+836.9	+12.6	+3.5	+24.3	+26.3	+12.5
2026	-16.9	+8.8	-1.6	+2.1	+12.8	+2.8	-5.8	-10.5	-12.9	-8.9	+7.7

Compare stocks

ABVX

Buy ABVX

Market cap

$8.00B

-

Price / Earnings ratio

-15.60

-

Price / Sales ratio

1,335.25

-

Dividend yield

0.00%

-

Average volume

906,014

-

Earnings per share

$-5.94

-

Abivax SA American Depositary Shares (ABVX) Stock

Key stats

Compare with ABVX

Recent news

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

4 Biotech Stocks to Watch as Potential Takeover Targets

4 Biotech Stocks to Watch as Potential Takeover Targets

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

4 Biotech Stocks to Watch as Potential Takeover Targets

4 Biotech Stocks to Watch as Potential Takeover Targets

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?

Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

Abivax: Wall Street Catches Up to the Data

Abivax: Wall Street Catches Up to the Data

ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds

ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds

Abivax nears $11 billion valuation after fundraising eases M&A pressure

Abivax nears $11 billion valuation after fundraising eases M&A pressure

ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns

ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns

Abivax shares jump as updated trial data eases safety concerns

Abivax shares jump as updated trial data eases safety concerns

About Abivax SA American Depositary Shares

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade